Urinary matrix metalloproteinases as a potential screening test for gynecologic malignancies

Gynecologic Oncology

Volumn 90, Issue 2, 2003, Pages 435-442

  Bazzett, Lisa B ^a   Magnus, Manya ^b   Taylor, Douglas D ^c   Gercel Taylor, Cicek ^c  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b TULANE UNIVERSITY   (United States)

^c University of Louisville School of Medicine   (United States)

Author keywords

Gynecologic malignancies; Urinary matrix metalloproteinases

Indexed keywords

GELATINASE A; GELATINASE B; ISOENZYME; MATRIX METALLOPROTEINASE;

ARTICLE; CANCER CLASSIFICATION; CANCER SCREENING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; ENDOMETRIUM CANCER; FEASIBILITY STUDY; FEMALE; GEL ELECTROPHORESIS; GYNECOLOGIC CANCER; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PREDICTION; PRIORITY JOURNAL; URINALYSIS; UTERINE CERVIX CANCER; VULVA CANCER; ZYMOGRAPHY;

EID: 0042624791     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(03)00334-2     Document Type: Article

References (24)

1. Liotta L.A., Rao N., Wewer U.M. Biochemical interactions of tumor cells with the basement membrane. Annu Rev Biochem. 55:1986;1037-1057.
2. Danø K., Andreasen P.A., Grøndahl-Hansen J., Kristensen P., Nielsen L.S., Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res. 44:1985;139-266.
3. Woessner J.F. Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 5:1991;2145-2154.
4. Huang L.-W., Garrett A.P., Bell D.A., Welch W.R., Berkowitz R.S., Mok S.C. Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors. Gynecol Oncol. 77:2000;369-376. (doi: 10.1006/gyno.2000.5806).
5. Wu X., Li H., Kang L., Li L., Wang W., Shan B. Activated matrix metalloproteinase-2 - a potential marker of prognosis for epithelial ovarian cancer. Gynecol Oncol. 84:2002;126-134. (doi: 10.1006/gyno.2001.6477).
6. Naylor M.S., Stamp G.W., Davies B.D., Balkwill F.R. Expression and activity of MMPs and their regulators in ovarian cancer. Int J Cancer. 58:1994;50-56.
7. Westerlund A., Apaja-Sarkkinen M., Höyhtyä M., Puistola U., Turpeenniemi-Hujanen T. Gelatinase A-immunoreactive protein in ovarian lesions - prognostic value in epithelial ovarian cancer. Gynecol Oncol. 75:1999;91-98. (doi: 10.1006/gyno.1999.5533).
8. Garzetti G.G., Ciavatini A., Lucarini G., Goteri G., De Nictolis M., Garbisa S., Masiero L., Romanini C., Graziella B. Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystadenocarcinomas clinical and prognostic implications . Anticancer Res. 15:1995;2799-2804.
9. Lengyel E., Schmalfeldt B., Konik E., Späthe K., Härting K., Fenn A., Berger U., Fridman R., Schmitt M., Prechtel D., Kuhn W. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol Oncol. 82:2001;291-298. (doi: 10.1006/gyno.2001.6243).
10. Schmalfeldt B., Prechtel D., Härting K., Späthe K., Rutke S., Konik E., Fridman R., Berger U., Schmitt M., Kuhn W., Lengyel E. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res. 7:2001;2396-2404.
11. Davidson B., Goldberg I., Kopolovic J., Lerner-Geva L., Gotlieb W.H., Weis B., Ben-Baruch G., Reich R. Expression of matrix metalloproteinase-9 in squamous cell carcinoma of the uterine cervix - clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. Gynecol Oncol. 72:1999;380-386. (doi: 10.1006/gyno. 1998.5285).
12. Talvensaari-Mattila A., Apaja-Sarkkinen M., Höyhtyä M., Westerlund A., Puistola U., Turpeenniemi-Hujanen T. Matrix metalloproteinase 2 immunoreactive protein appears early in cervical epithelial dedifferentiation. Gynecol Oncol. 72:1999;306-311. (doi: 10.1006/gyno.1998.5157).
13. Brummer O., Böhmer G., Hollwitz B., Flemming P., Petry K.-U., Kühnle H. MMP-1 and MMP-2 in the cervix uteri in different steps of malignant transformation - an immunohistochemical study. Gynecol Oncol. 84:2002;222-227. (doi: 10.1006/gyno.2001.6413).
14. Garzetti G.G., Ciavattini A., Lucarini G., Goteri G., De Nictolis M., Romanini C., Biagini G. Recurrence patterns in locally advanced cervical carcinoma role of nodal status and 72-kDa metalloproteinse index . Gynecol Oncol. 61:1996;83-89. (doi: 10.1006/gyno.1996.0101).
15. Di Nezza L.A., Misajon A., Zhang J., Jobling T., Quinn M.A., Ostör A.G., Nie G., Lopata A., Salamonsen L.A. Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion. Cancer. 94:2002;1466-1475.
16. Iurlaro M., Loverro G., Vacca A., Cormio G., Ribatti D., Minischetti M., Ria R., Bruno M., Selvaggi L. Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with upgrading and myometrial invasion in endometrial carcinoma. Eur J Clin Invest. 29:1999;793-801.
17. Inoue Y., Abe K., Obata K., Yoshioka T., Ohmura G., Doh K., Yamamoto K., Hoshiai H., Noda K. Immunohistochemical studies on matrix metalloproteinase-9 (MMP-9) and type-IV collagen in endometrial carcinoma. J Obstet Gynaecol Res. 23:1997;139-145.
18. Sier C.F.M., Casetta G., Verheijen J.H., Tizzani A., Agape V., Kos J., Blasi F., Hanemaaijer R. Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma a comparison with clinically used tumor markers . Clin Cancer Res. 6:2000;2333-2340.
19. Gerhards S., Jung K., Koenig F., Daniltchenko D., Hauptmann S., Schnorr Loening S.A. Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma. Urology. 57:2001;675-679.
20. Moses M.A., Wiederschain D., Loughlin K.R., Zurakowski D., Lamb C.C., Freeman M.R. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res. 58:1998;1395-1399.
21. Goldberg G.I., Strongin A., Collier I.E., Genrich L.T., Marmer B.L. Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J Biol Chem. 267:1992;4583-4591.
22. Bianco F.J. Jr, Gervasi D.C., Tiguert R., Grihnon D.J., Pontes E., Crissman J.D., Fridman R., Wood D.P. Jr. Matrix metalloproteinase-9 expression in bladder washes from bladder cancer patients predicts pathological stage and grade. Clin Cancer Res. 4:1998;3011-3016.
23. Young T.N., Rodriguez G.C., Rinehart A.R., Bast R.C. Jr, Pizzo S.V., Stack M.S. Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma purification of matrix metalloproteinase 2 . Gynecol Oncol. 62:1996;89-99. (doi: 10.1006/gyno.1996.0195).
24. Davidson B., Goldberg I., Kopolovic J., Lerner-Geva L., Gotlieb W.H., Ben-Baruch G., Riech R. MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma - a clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. Gynecol Oncol. 73:1999;372-382. (doi: 10.1006/gyno.1999.5381).